Iris Melanoma

  • Arun D. SinghEmail author
  • Bertil E. Damato


Iris melanoma is least frequent of all uveal melanomas. Because of anterior location, iris melanoma is diagnosed and treated when relatively small compared to tumors located in ciliary body and choroid. Melanoma located in the peripheral iris may represent anterior extension of a ciliary body tumor, and therefore it is of paramount importance to examine the ciliary body in cases of iris melanoma when all iris margins of the tumors are not visualized. Iris melanoma may be circumscribed or diffuse. Tapioca iris melanoma is a rare variant of diffuse iris melanoma. Slit-lamp examination, gonioscopy, and ultrasound biomicroscopy (UBM) allow staging of the tumor to guide the most appropriate treatment. Iris melanomas are managed by observation, incisional biopsy, excisional biopsy, or radiotherapy depending upon the size, extent, and visual potential. Iris melanomas tend to be less aggressive in comparison to melanomas in other uveal locations.


Iris melanoma Tapioca Ring-shaped Iridectomy Iridocyclectomy 


  1. 1.
    Rootman J, Gallagher RP. Color as a risk factor in iris melanoma. Am J Ophthalmol. 1984;98(5):558–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Khan S, Finger PT, Yu GP, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130(1):57–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Qian Y, Zakov ZN, Schoenfield L, et al. Iris melanoma arising in iris nevus in oculo(dermal) melanocytosis. Surv Ophthalmol. 2008;53(4):411–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Shields CL, Kaliki S, Hutchinson A, et al. Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology. 2013;120(4):766–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Medina CA, Biscotti CV, Singh N, et al. Diagnostic cytologic features of uveal melanoma. Ophthalmology. 2015;122(8):1580–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Scholz SL, Moller I, Reis H, et al. Frequent GNAQ, GNA11, and EIF1AX mutations in iris melanoma. Invest Ophthalmol Vis Sci. 2017;58(9):3464–70. Scholar
  7. 7.
    de Lange MJ, Razzaq L, Versluis M, et al. Distribution of GNAQ and GNA11 mutation signatures in uveal melanoma points to a light dependent mutation mechanism. PLoS One. 2015;10(9):e0138002.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Krishna Y, Kalirai H, Thornton S, et al. Genetic findings in treatment-naive and proton-beam-radiated iris melanomas. Br J Ophthalmol. 2016;100(7):1012–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Harbour JW, Wilson D, Finger PT, et al. Gene expressing profiling of iris melanomas. Ophthalmology. 2013;120(1):213, e1–3.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Zografos L, Uffer S. Tumeurs iriennes pigmentées. In: Zografos L, editor. Tumeursintraoculaires. Paris: Masson; 2002. p. 281–313.Google Scholar
  12. 12.
    Arentsen JJ, Green WR. Melanoma of the iris: report of 72 cases treated surgically. Ophthalmic Surg. 1975;6(2):23–37.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108(1):172–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Shah PG, Shields CL, Shields JA, et al. Band keratopathy secondary to an iris melanoma. Cornea. 1991;10(1):67–9.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Brown D, Boniuk M, Font RL. Diffuse malignant melanoma of iris with metastases. Surv Ophthalmol. 1990;34(5):357–64.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Char DH, Crawford JB, Gonzales J, et al. Iris melanoma with increased intraocular pressure. Differentiation of focal solitary tumors from diffuse or multiple tumors. Arch Ophthalmol. 1989;107(4):548–51.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Demirci H, Shields CL, Shields JA, et al. Diffuse iris melanoma: a report of 25 cases. Ophthalmology. 2002;109(8):1553–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Ajamil Rodanes S, Garcia-Alvarez C, Saornil Alvarez MA, et al. Melanomalytic glaucoma secondary to iris melanoma. Arch Soc Esp Oftalmol. 2017;92(8):379–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Jakobiec FA, Silbert G. Are most iris “melanomas” really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981;99(12):2117–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Harley MR, Rao R, Lally SE, et al. Malignant transformation of multifocal tapioca iris nevus in a child. J AAPOS. 2017;21(4):340–2.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Iwamoto T, Reese AB, Mund ML. Tapioca melanoma of the iris. 2. Electron microscopy of the melanoma cells compared with normal iris melanocytes. Am J Ophthalmol. 1972;74(5):851–61.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Reese AB, Mund ML, Iwamoto T. Tapioca melanoma of the iris. 1. Clinical and light microscopy studies. Am J Ophthalmol. 1972;74(5):840–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Haddad R, Konrad K, Stur M. Fine structure of tapioca melanoma of the iris. Doc Ophthalmol. 1985;61(2):157–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Zakka KA, Foos RY, Sulit H. Metastatic tapioca iris melanoma. Br J Ophthalmol. 1979;63(11):744–9.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Singh AD. Tumors of the uvea: benign melanocytic tumors. In: Singh AD, Damato BE, Pe’er J, et al., editors. In clinical ophthalmic oncology. Philadelphia: Saunders-Elsevier; 2007.Google Scholar
  26. 26.
    Taban M, Sears JE, Singh AD. Ciliary body naevus. Eye. 2007;21(12):1528–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Hale PN, Allen RA, Straatsma BR. Benign melanomas (nevi) of the choroid and ciliary body. Arch Ophthalmol. 1965;74(4):532–8.PubMedCrossRefGoogle Scholar
  28. 28.
    LoRusso FJ, Boniuk M, Font RL. Melanocytoma (magnocellular nevus) of the ciliary body: report of 10 cases and review of the literature. Ophthalmology. 2000;107(4):795–800.PubMedCrossRefGoogle Scholar
  29. 29.
    Frangieh GT, el Baba F, Traboulsi EI, et al. Melanocytoma of the ciliary body: presentation of four cases and review of nineteen reports. Surv Ophthalmol. 1985;29(5):328–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Damato EM, Damato B, Sibbring JS, et al. Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1637–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Vasquez LM, Pavlin CJ, McGowan H, et al. Ring melanoma of the ciliary body: clinical and ultrasound biomicroscopic characteristics. Can J Ophthalmol. 2008;43(2):229–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Demirci H, Shields CL, Shields JA, et al. Ring melanoma of the anterior chamber angle: a report of fourteen cases. Am J Ophthalmol. 2001;132(3):336–42.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Aziz HA, Modi YS, Plesec TP, et al. Amelanotic Irido-Ciliary ring melanoma: a clinicopathological correlation. Ocul Oncol Pathol. 2016;2(3):153–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Kathil P, Milman T, Finger PT. Characteristics of anterior uveal melanocytomas in 17 cases. Ophthalmology. 2011;118(9):1874–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Shields JA, Shields CL. Cysts of the iris pigment epithelium. What is new and interesting? The 2016 Jose Rizal International Medal Lecture. Asia Pac J Ophthalmol (Phila). 2017;6(1):64–9. Scholar
  36. 36.
    Augsburger JJ, Affel LL, Benarosh DA. Ultrasound biomicroscopy of cystic lesions of the iris and ciliary body. Trans Am Ophthalmol Soc. 1996;94:259–71; discussion 71–4.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Fine N, Pavlin CJ. Primary cysts in the iridociliary sulcus: ultrasound biomicroscopic features of 210 cases. Can J Ophthalmol. 1999;34(6):325–9.PubMedGoogle Scholar
  38. 38.
    Shields CL, Shields JA, Cook GR, et al. Differentiation of adenoma of the iris pigment epithelium from iris cyst and melanoma. Am J Ophthalmol. 1985;100(5):678–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Rao A, Gupta V, Bhadange Y, et al. Iris cysts: a review. Semin Ophthalmol. 2011;26(1):11–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Lois N, Shields CL, Shields JA, et al. Primary cysts of the iris pigment epithelium. Clinical features and natural course in 234 patients. Ophthalmology. 1998;105(10):1879–85.PubMedCrossRefGoogle Scholar
  41. 41.
    Denny MR, Seider MI. Surgical cystotomy of a large iris pigment epithelial cyst with microinstrumentation. Ocul Oncol Pathol. 2018;5:119–21.PubMedCrossRefGoogle Scholar
  42. 42.
    Collins ME, Hariprasad SM. Images in clinical medicine. Free-floating iris cyst. N Engl J Med. 2010;362(18):1720.PubMedCrossRefGoogle Scholar
  43. 43.
    Al-Kahtani E, Alkatan HM. Surgical treatment and histopathology of a symptomatic free-floating primary pigment epithelial iris cyst in the anterior vitreous. Middle East Afr J Ophthalmol. 2011;18(4):331–2.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Georgalas I, Petrou P, Papaconstantinou D, et al. Iris cysts: A comprehensive review on diagnosis and treatment. Surv Ophthalmol. 2018;63(3):347–64.PubMedCrossRefGoogle Scholar
  45. 45.
    Hashida N, Ohguro N, Morimoto Y, et al. Ultrastructural appearance of iris flocculi associated with a thoracic aortic aneurysm and dissections. Br J Ophthalmol. 2009;93(10):1409–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Shields JA, Magrath GN, Shields C, et al. Dissecting aortic aneurysm 55 years after diagnosis of iris flocculi. Ocul Oncol Pathol. 2016;2(4):222–5.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Naumann G, Green WR. Spontaneous nonpigmented iris cysts. Arch Ophthalmol. 1967;78(4):496–500.PubMedCrossRefGoogle Scholar
  48. 48.
    Lois N, Shields CL, Shields JA, et al. Primary iris stromal cysts. A report of 17 cases. Ophthalmology. 1998;105(7):1317–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Behrouzi Z, Khodadoust A. Epithelial iris cyst treatment with intracystic ethanol irrigation. Ophthalmology. 2003;110(8):1601–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Lockington D, Altaie R, Moore S, et al. Successful management of secondary iris cysts with viscoelastic-assisted endophotocoagulation. JAMA Ophthalmol. 2014;132(3):354–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Buckley RJ. Pathogenesis of the ICE syndrome. Br J Ophthalmol. 1994;78(8):595–6.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Bourne WM. Biology of the corneal endothelium in health and disease. Eye. 2003;17(8):912–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Wilson MC, Shields MB. A comparison of the clinical variations of the iridocorneal endothelial syndrome. Arch Ophthalmol. 1989;107(10):1465–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Le QH, Sun XH, Xu JJ. In-vivo confocal microscopy of iridocorneal endothelial syndrome. Int Ophthalmol. 2009;29(1):11–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Chiou AG, Kaufman SC, Beuerman RW, et al. Confocal microscopy in the iridocorneal endothelial syndrome. Br J Ophthalmol. 1999;83(6):697–702.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Levy SG, McCartney AC, Baghai MH, et al. Pathology of the iridocorneal-endothelial syndrome. The ICE-cell. Invest Ophthalmol Vis Sci. 1995;36(13):2592–601.PubMedGoogle Scholar
  57. 57.
    Shields CL, Shields JA, Gross NE, et al. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104(8):1265–76.PubMedCrossRefGoogle Scholar
  58. 58.
    Shields CL, Kaliki S, Crabtree GS, et al. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea. 2015;34(1):42–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Shields JA, Shields CL, Kiratli H, et al. Metastatic tumors to the iris in 40 patients. Am J Ophthalmol. 1995;119(4):422–30.PubMedCrossRefGoogle Scholar
  60. 60.
    Augsburger JJ. Fine needle aspiration biopsy of suspected metastatic cancers to the posterior uvea. Trans Am Ophthalmol Soc. 1988;86:499–560.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Kanthan GL, Jayamohan J, Yip D, et al. Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. Clin Exp Ophthalmol. 2007;35(6):553–65.PubMedCrossRefGoogle Scholar
  62. 62.
    Biscotti CV, Singh AD. Uveal metastases. Monogr Clin Cytol. 2012;21:17–30.PubMedCrossRefGoogle Scholar
  63. 63.
    Shields JA, Shields CL, Lally SE, et al. Iris melanoma in a child simulating juvenile xanthogranuloma. Middle East Afr J Ophthalmol. 2018;25(2):115–7.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Janku L, Singh AD. Transillumination. In: Bergstrom C, Baker Hubbard C, Wells JR, et al., editors. Pocket guide to ocular oncology and pathology. Heidelberg: Springer; 2012.Google Scholar
  65. 65.
    Bianciotto C, Shields CL, Guzman JM, et al. Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology. 2011;118(7):1297–302.PubMedGoogle Scholar
  66. 66.
    Skalet AH, Li Y, Lu CD, et al. Optical coherence tomography angiography characteristics of iris melanocytic tumors. Ophthalmology. 2017;124(2):197–204. Epub Nov 14.CrossRefPubMedGoogle Scholar
  67. 67.
    Hau SC, Papastefanou V, Shah S, et al. Evaluation of iris and iridociliary body lesions with anterior segment optical coherence tomography versus ultrasound B-scan. Br J Ophthalmol. 2015;99(1):81–6. Epub 2014 Aug 4.CrossRefPubMedGoogle Scholar
  68. 68.
    Maberly DA, Pavlin CJ, McGowan HD, et al. Ultrasound biomicroscopic imaging of the anterior aspect of peripheral choroidal melanomas. Am J Ophthalmol. 1997;123(4):506–14.PubMedCrossRefGoogle Scholar
  69. 69.
    Marigo FA, Finger PT, McCormick SA, et al. Iris and ciliary body melanomas: ultrasound biomicroscopy with histopathologic correlation. Arch Ophthalmol. 2000;118(11):1515–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Singh AD, Pelayes DE, Brainard JA, et al. History, indications, techniques and limitations. Monogr Clin Cytol. 2012;21:1–9.PubMedGoogle Scholar
  71. 71.
    Gokhale R, Medina CA, Biscotti CV, et al. Diagnostic fine-needle aspiration biopsy for iris melanoma. Asia Pac J Ophthalmol (Phila). 2015;4(2):89–91.CrossRefGoogle Scholar
  72. 72.
    Chronopoulos A, Kilic E, Joussen AM, et al. Small incision iris tumour biopsy using a cavernous sampling forceps. Br J Ophthalmol. 2014;98(11):1539–42. Epub 2014 Jun 25.CrossRefPubMedGoogle Scholar
  73. 73.
    Finger PT, Milman T. Microincision, aspiration cutter-assisted multifocal iris biopsy for melanoma. Eur J Ophthalmol. 2017;27(1):62–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology. 1996;103(12):2017–27; discussion 27–8.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Harbour JW, Augsburger JJ, Eagle RC Jr. Initial management and follow-up of melanocytic iris tumors. Ophthalmology. 1995;102(12):1987–93.PubMedCrossRefGoogle Scholar
  76. 76.
    Matthews BJ, Mudhar HS, Rennie IG. Trans-corneal fine cannula aspiration: Rycroft cannula aspiration technique for sampling iris tumours. Br J Ophthalmol. 2012;96(3):329–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Milman T, Petousis V, McCormick SA, et al. Anterior segment tumor aspiration cutter-assisted biopsy: experience with pathology. Am J Ophthalmol. 2011;152(5):776–83 e1.PubMedCrossRefGoogle Scholar
  78. 78.
    Pe’er J, Frenkel S. Sector iridectomy of iris melanoma: a novel technique for excising the melanoma extraocularly. Br J Ophthalmol. 2011;95(10):1474–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Klauber S, Jensen PK, Prause JU, et al. Surgical treatment of iris and ciliary body melanoma: follow-up of a 25-year series of patients. Acta Ophthalmol. 2012;90(2):122–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Tsimpida M, Hungerford J, Arora A, et al. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma. Eye. 2011;25(12):1607–11.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Shields CL, Naseripour M, Shields JA, et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135(5):648–56.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Reese AB, Cleasby GW. The treatment of iris melanoma. Am J Ophthalmol. 1959;47(5, Part 2):118–25.PubMedCrossRefGoogle Scholar
  83. 83.
    Shields CL, Kancherla S, Patel J, et al. Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology. 2012;119(2):407–14.PubMedCrossRefGoogle Scholar
  84. 84.
    Popovic M, Ahmed IIK, DiGiovanni J, et al. Radiotherapeutic and surgical management of iris melanoma: a review. Surv Ophthalmol. 2017;62(3):302–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Weisbrod DJ, Pavlin CJ, Xu W, et al. Long-term follow-up of 42 patients with small ciliary body tumors with ultrasound biomicroscopy. Am J Ophthalmol. 2010;149(4):616–22.PubMedCrossRefGoogle Scholar
  86. 86.
    Damato B, Groenewald C. Uveal malignant melanoma: management options – resection techniques. In: Singh AD, Damato BE, Pe’er J, et al., editors. Clinical ophthalmic oncology. Philadelphia: Saunders Elsevier; 2007.Google Scholar
  87. 87.
    Rones B, Zimmerman LE. The prognosis of primary tumors of the iris treated by iridectomy. AMA Arch Ophthalmol. 1958;60(2):193–205.PubMedCrossRefGoogle Scholar
  88. 88.
    Batioglu F, Gunalp I. Malignant melanomas of the iris. Jpn J Ophthalmol. 1998;42(4):281–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Cardine S, Labetoulle M, Kirsch O, et al. [Iris melanomas. A retrospective study of 11 patients treated by surgical excision]. J Fr Ophtalmol. 2003;26(1):31–7.Google Scholar
  90. 90.
    Alio JL, Fine IH. Minimizing incisions and maximizing outcomes in cataract surgery. New York: Springer; 2010.CrossRefGoogle Scholar
  91. 91.
    Rospond-Kubiak I, Damato B. The surgical approach to the management of anterior uveal melanomas. Eye (Lond). 2014;28(6):741–7.CrossRefGoogle Scholar
  92. 92.
    Allen JC. Incidence of photophobia in peripheral and sector iridectomy. Am J Ophthalmol. 1976;82(2):316–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Hood CT, Schoenfield LR, Torres V, et al. Iris melanoma. Ophthalmology. 2011;118(1):221–2.PubMedCrossRefGoogle Scholar
  94. 94.
    Singh AD. Small incision guarded hydroaspiration of iris lesions. Br J Ophthalmol. 2017;101(11):1570–5.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Scheie HG, Yanoff M. Pseudomelanoma of the ciliary body. Report of a patient. Arch Ophthalmol. 1967;77(1):81–3.PubMedCrossRefGoogle Scholar
  96. 96.
    El-Harazi SM, Kellaway J, Font RL. Melanocytoma of the ciliary body diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol. 2000;22(6):394–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Rummelt V, Naumann GO, Folberg R, et al. Surgical management of melanocytoma of the ciliary body with extrascleral extension. Am J Ophthalmol. 1994;117(2):169–76.PubMedCrossRefGoogle Scholar
  98. 98.
    Fabian ID, Thaung C, AlHarby L, et al. Late solitary extraocular recurrence from previously resected iris melanoma. Am J Ophthalmol. 2017;181:97–105. Epub Jul 1.CrossRefPubMedGoogle Scholar
  99. 99.
    Demirci H, Shields CL, Shields JA, et al. Ring melanoma of the ciliary body: report on twenty-three patients. Retina. 2002;22(6):698–706; quiz 852–3.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 2001;132(3):328–35.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Krema H, Simpson ER, Pavlin CJ, et al. Management of ciliary body melanoma with iodine-125 plaque brachytherapy. Can J Ophthalmol. 2009;44(4):395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Fernandes BF, Krema H, Fulda E, et al. Management of iris melanomas with 125Iodine plaque radiotherapy. Am J Ophthalmol. 2010;149(1):70–6.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Razzaq L, de Keizer RJ. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes? Br J Ophthalmol. 2010;94(11):1549–50.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Shields CL, Shah SU, Bianciotto CG, et al. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology. 2013;120(1):55–61.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Agraval U, Sobti M, Russell HC, et al. Use of Ruthenium-106 brachytherapy for iris melanoma: the Scottish experience. Br J Ophthalmol. 2018;102(1):74–8. Epub 2017 Jun 9.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Chaugule SS, Finger PT. Regression patterns of iris melanoma after Palladium-103 ((103)Pd) plaque brachytherapy. Ophthalmology. 2017;124(7):1023–30. Epub Apr 1.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys. 2005;63(1):109–15.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Rundle P, Singh AD, Rennie I. Proton beam therapy for iris melanoma: a review of 15 cases. Eye. 2007;21(1):79–82.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65(3):780–7.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Rahmi A, Mammar H, Thariat J, et al. Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1515–21.PubMedCrossRefGoogle Scholar
  111. 111.
    Konstantinidis L, Roberts D, Errington RD, et al. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol. 2013;97(4):471–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Singh AD, Dupps WJ Jr, Biscotti CV, et al. Limbal stem cell preservation during proton beam irradiation for diffuse iris melanoma. Cornea. 2017;36(1):119–22.PubMedCrossRefGoogle Scholar
  113. 113.
    Leblanc A, Lumbroso-Le-Rouic L, Desjardins L, et al. Diffuse iris melanoma: conservative treatment with proton beam therapy after limbal stem cell preservation or enucleation?. Ocul Oncol Pathol. 2019. [epub ahead of print].Google Scholar
  114. 114.
    Tan AN, Hoevenaars JG, Webers CA, et al. Baerveldt implant for secondary glaucoma due to iris melanoma. Clin Ophthalmol. 2010;4:407–9.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Sharkawi E, Oleszczuk JD, Bergin C, et al. Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy. Br J Ophthalmol. 2012;96(8):1104–7.PubMedCrossRefGoogle Scholar
  116. 116.
    Trichopoulos N, Damato B. Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):1573–5.PubMedCrossRefGoogle Scholar
  117. 117.
    Sandinha MT, Kacperek A, Errington RD, et al. Recurrence of iris melanoma after proton beam therapy. Br J Ophthalmol. 2014;98(4):484–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Riechardt AI, Klein JP, Cordini D, et al. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects. Graefes Arch Clin Exp Ophthalmol. 2018;256(7):1325–32. Epub 2018 Feb 20.CrossRefPubMedGoogle Scholar
  119. 119.
    Riechardt AI, Karle B, Cordini D, et al. Proton therapy of iris melanoma with 50 CGE: influence of target volume on clinical outcome. Strahlenther Onkol. 2017;193(11):943–50.PubMedCrossRefGoogle Scholar
  120. 120.
    Aponte EP, Stern RM, Hayden BC, et al. Iridocorneal endothelial syndrome. Adv Ocul Care. 2010:31–2.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Ophthalmic Oncology, Cole Eye InstituteCleveland ClinicClevelandUSA
  2. 2.Nuffield Department of Clinical NeurosciencesUniversity of Oxford, John Radcliffe HospitalOxfordUK

Personalised recommendations